Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: Results from a single practice

International Journal of Radiation Oncology Biology Physics

Volumn 48, Issue 1, 2000, Pages 111-117

  Brachman, David G ^a   Thomas, Theresa ^b   Hilbe, Joseph ^c   Beyer, David C ^a  

^a Arizona Oncology Services   (United States)

^b Foundation for Cancer Research and Education   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Brachytherapy; External beam; Prostate cancer; PSA

Indexed keywords

IODINE 125; PALLADIUM; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER REGISTRY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DATA BASE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE TUMOR; SURVIVAL RATE; TECHNIQUE; TREATMENT OUTCOME;

AGED; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; NEOPLASM STAGING; PALLADIUM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0034255569     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00598-8     Document Type: Article

References (20)

1. Lee W.R., Hanks G.E., Schultheiss T.E., et al. Localized prostate cancer treatment by external-beam radiotherapy alone Serum prostate-specific antigen-driven outcome analysis . J Clin Oncol. 13:1995;464-469.
2. Zagars GK, Pollack A, Kavadi VS, vonEshenback AC. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:293-306.
3. 125I prostate implantation. Int J Radiat Oncol Biol Phys. 37:1997;559-563.
4. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280:1998;969-974.
5. Ragde H., Blasko J.C., Grimm P.D., et al. Brachytherapy for clinically localized prostate cancer Results at 7- and 8-year follow-up . Semin Surg Oncol. 13:1997;438-443.
6. 125I implantation for stage T1/T2 prostate carcinoma. J Clin Oncol. 14:1996;449-453.
7. Koprowski C., Berkenstock K., Borofski A., et al. External beam irradiation versus 125 iodine implant in the definitive treatment of prostate carcinoma. Int J Radiat Oncol Biol Phys. 21:1991;955-960.
8. Pisansky T.M., Cha S.S., Earle J.D., et al. Prostate specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol. 11:1993;2158-2166.
9. Pisansky T.M., Kahn M.J., Rasp G.M., et al. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate cancer. Cancer. 79:1997;337-344.
10. Gleason D.F. Histologic grade, clinical stage, and patient age in prostate cancer. NCI Monogr. 7:1988;15-18.
11. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;36:1035-1041.
12. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
13. Merrick G.S., Butler W.M., Farthing W.H. Jr, et al. The impact of Gleason score accuracy as a criterion for prostate brachytherapy patient selection. J Brachy Int. 14:1998;113-121.
14. Wurzer J.C., Al-Saleem T.I., Hanlon A.L., Freedman G.M., Patchefsky A., Hanks G.E. Histopathologic review of prostate biopsies from patients referred to a comprehensive cancer center. Cancer. 83:1998;753-759.
15. Laverdiere J., Gomez J.L., Cusan L., et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 37:1997;247-252.
16. Kupelian P., Katcher J., Levin H., et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1-T2 prostate cancer Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores . Cancer Sci Am. 3:1997;78-87.
17. Pollack A., Zagars G.K. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys. 39:1997;1011-1018.
18. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment five year outcomes, treatment optimization, and future directions . Int J Radiat Oncol Biol Phys. 41:1998;501-510.
19. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
20. Catalona W.J., Smith D.S. 5-year tumor recurrence rates after anatomical radical retro-pubic prostatectomy for prostate cancer. J Urol. 152:1994;1837-1842.